fda category 2 bulk drug substances bpc-157 compounding list RFK Jr.'s peptide push could unleash risky drugs BREAKING: The FDA just reversed
Description
A reasonable bar would be at least one published phase 2 trial showing clinical efficacy with acceptable safety in humans
Next, Zhang et al
Salvio G, Cutini M, Ciarloni A, Giovannini L, Perrone M, Balercia G
Significance of Negative Post-Treatment 18-FDG PET/CT Imaging in Patients with p16/HPV-positive Oropharyngeal Cancer
